Marisa Wexler, MS, senior science writer —

Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.

Articles by Marisa Wexler

FDA OKs Clinical Trial Testing Cudetaxestat With Ofev, Esbriet

The U.S. Food and Drug Administration (FDA) has authorized Blade Therapeutics to begin a Phase 1 clinical trial evaluating pharmacological interactions between its investigational medication, cudetaxestat (BLD-0409), and two approved treatments for idiopathic pulmonary fibrosis (IPF). The trial will enroll an estimated 86 healthy individuals, who…

MyMD Earns Patent for Investigational Therapy MYMD-1

MyMD Pharmaceuticals has secured a 13th U.S. patent protecting its experimental therapy MYMD-1, which is being investigated as a potential treatment for idiopathic pulmonary fibrosis (IPF) and other diseases. The new patent (11,096,933), “Method of Treating Disorders Associated with Chronic Inflammation,” covers the administration of MYMD-1 to…

Many Wait a Year or Longer for PF Diagnosis, Survey Finds

For more than 40% of people with pulmonary fibrosis (PF), obtaining an accurate diagnosis takes a year or longer, according to a European survey. As noted by the international team of researchers who conducted the study, survey findings highlighted “a major need for more information and support during and…

Blood Levels of Molecules May Distinguish IPF From Other ILDs

Measuring the levels of certain molecules in the blood could be useful for distinguishing idiopathic pulmonary fibrosis (IPF) from other types of lung disease, according to a recent study. The study, “Serum Biomarkers in Differential Diagnosis of Idiopathic Pulmonary Fibrosis and Connective Tissue Disease-Associated Interstitial Lung Disease,”…

Switching Between Antifibrotics May Help IPF Patients Live Longer

Switching antifibrotic treatment is generally well-tolerated among people with idiopathic pulmonary fibrosis (IPF), and those who did generally lived several years longer than those who did not, a study from Japan reports. Findings suggest that switching from one antifibrotic to another “is feasible and may improve prognosis [disease course]…

Your PF Community

Woman laying down reading

Visit the Pulmonary Fibrosis News forums to connect with others in the PF community.

View Forums